Revenue and net profit grew year-over-year for the quarter and six months ended September 30, 2024, with strong operating margins and increased cash reserves. Auditors found no material misstatements, and the company remains focused on its core pharmaceuticals segment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.